Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 2682861, 12 pages
https://doi.org/10.1155/2017/2682861
Research Article

Protective Effects of Pyridoxamine Supplementation in the Early Stages of Diet-Induced Kidney Dysfunction

1Department of Drug Science and Technology, University of Turin, Turin, Italy
2Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
3Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy

Correspondence should be addressed to R. Mastrocola; ti.otinu@alocortsam.alleaffar

Received 2 August 2017; Accepted 3 October 2017; Published 29 October 2017

Academic Editor: Goutam Ghosh Choudhury

Copyright © 2017 F. Chiazza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Ritz and S. R. Orth, “Nephropathy in patients with type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 341, no. 15, pp. 1127–1133, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Afkarian, M. C. Sachs, B. Kestenbaum et al., “Kidney disease and increased mortality risk in type 2 diabetes,” Journal of the American Society of Nephrology, vol. 24, no. 2, pp. 302–308, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Gnudi, R. J. Coward, and D. A. Long, “Diabetic nephropathy: perspective on novel molecular mechanisms,” Trends in Endocrinology & Metabolism, vol. 27, no. 11, pp. 820–830, 2016. View at Publisher · View at Google Scholar
  4. M. E. Williams, W. K. Bolton, R. G. Khalifah, T. P. Degenhardt, R. J. Schotzinger, and J. B. McGill, “Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy,” American Journal of Nephrology, vol. 27, no. 6, pp. 605–614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. R. G. Khalifah, J. W. Baynes, and B. G. Hudson, “Amadorins: novel post-Amadori inhibitors of advanced glycation reactions,” Biochemical and Biophysical Research Communications, vol. 257, no. 2, pp. 251–258, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. E. J. Lewis, T. Greene, S. Spitalewiz et al., “Pyridorin in type 2 diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 1, pp. 131–136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Turgut and W. K. Bolton, “Potential new therapeutic agents for diabetic kidney disease,” American Journal of Kidney Diseases, vol. 55, no. 5, pp. 928–940, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Mastrocola, M. Collino, M. Rogazzo et al., “Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 305, no. 6, pp. G398–G407, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Suarez, R. Rajaram, A. L. Oronsky, and M. A. Gawinowicz, “Nonenzymatic glycation of bovine serum albumin by fructose (fructation). Comparison with the Maillard reaction initiated by glucose,” The Journal of Biological Chemistry, vol. 264, no. 7, pp. 3674–3679, 1989. View at Google Scholar · View at Scopus
  10. R. Mastrocola, D. Nigro, F. Chiazza et al., “Fructose-derived advanced glycation end-products drive lipogenesis and skeletal muscle reprogramming via SREBP-1c dysregulation in mice,” Free Radical Biology & Medicine, vol. 91, pp. 224–235, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Mastrocola, M. Collino, D. Nigro et al., “Accumulation of advanced glycation end-products and activation of the SCAP/SREBP lipogenetic pathway occur in diet-induced obese mouse skeletal muscle,” PLoS ONE, vol. 10, no. 3, Article ID e0119587, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Mastrocola, D. Nigro, A. S. Cento, F. Chiazza, M. Collino, and M. Aragno, “High-fructose intake as risk factor for neurodegeneration: key role for carboxy methyllysine accumulation in mice hippocampal neurons,” Neurobiology of Disease, vol. 89, pp. 65–75, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. E. D. Schleicher, E. Wagner, and A. G. Nerlich, “Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging,” The Journal of Clinical Investigation, vol. 99, no. 3, pp. 457–468, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. H. M. El-Bassossy, N. Dsokey, and A. Fahmy, “Characterization of vascular complications in experimental model of fructose-induced metabolic syndrome,” Toxicology Mechanisms and Methods, vol. 24, no. 8, pp. 536–543, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. T.-W. Lee, Y.-H. Kao, T.-I. Lee, C.-J. Chang, G.-S. Lien, and Y.-J. Chen, “Calcitriol modulates receptor for advanced glycation end products (RAGE) in diabetic hearts,” International Journal of Cardiology, vol. 173, no. 2, pp. 236–241, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. D.-H. Yang, T.-I. Chiang, I.-C. Chang, F.-H. Lin, C.-C. Wei, and Y.-W. Cheng, “Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis,” International Journal of Medical Sciences, vol. 11, no. 4, pp. 453–460, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Daroux, G. Prévost, H. Maillard-Lefebvre et al., “Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies,” Diabetes & Metabolism, vol. 36, no. 1, pp. 1–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Ott, K. Jacobs, E. Haucke, A. Navarrete Santos, T. Grune, and A. Simm, “Role of advanced glycation end products in cellular signaling,” Redox Biology, vol. 2, no. 1, pp. 411–429, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Wada and H. Makino, “Inflammation and the pathogenesis of diabetic nephropathy,” Clinical Science, vol. 124, no. 3, pp. 139–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Tanimoto, T. Gohda, S. Kaneko et al., “Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-/Ta mice,” Metabolism—Clinical and Experimental, vol. 56, no. 2, pp. 160–167, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Murakoshi, M. Tanimoto, T. Gohda et al., “Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-/Ta mice,” Diabetes Research and Clinical Practice, vol. 83, no. 2, pp. 183–189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. T. K. Abouzed, S. Munesue, A. Harashima et al., “Preventive effect of salicylate and pyridoxamine on diabetic nephropathy,” Journal of Diabetes Research, vol. 2016, Article ID 1786789, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. A. M. D. Watson, A. Soro-Paavonen, K. Sheehy et al., “Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice,” Diabetologia, vol. 54, no. 3, pp. 681–689, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Chiazza, A. Couturier-Maillard, E. Benetti et al., “Targeting the NLRP3 inflammasome to reduce diet-induced metabolic abnormalities in mice,” Molecular Medicine, vol. 21, no. 1, pp. 1025–1037, 2015. View at Publisher · View at Google Scholar
  25. M. Collino, E. Benetti, M. Rogazzo et al., “Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR- agonism correlates with impaired NLRP3 inflammasome activation,” Biochemical Pharmacology, vol. 85, no. 2, pp. 257–264, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Mastrocola, M. Collino, C. Penna et al., “Maladaptive modulations of NLRP3 inflammasome and cardioprotective pathways are involved in diet-induced exacerbation of myocardial ischemia/reperfusion injury in mice,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3480637, 12 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Yamamoto, I. Kato, T. Doi et al., “Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice,” The Journal of Clinical Investigation, vol. 108, no. 2, pp. 261–268, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Yuan, H. Sun, and Z. Sun, “Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN),” Lipids in Health and Disease, vol. 16, article 126, 2017. View at Publisher · View at Google Scholar
  29. T. Chavakis, A. Bierhaus, and P. P. Nawroth, “RAGE (receptor for advanced glycation end products): a central player in the inflammatory response,” Microbes and Infection, vol. 6, no. 13, pp. 1219–1225, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. M. P. Wautier, O. Chappey, S. Corda, D. M. Stern, A. M. Schmidt, and J. L. Wautier, “Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE,” American Journal of Physiology Endocriology and Metabolism, vol. 280, no. 5, pp. E685–E694, 2001. View at Google Scholar
  31. M. D. Oldfield, L. A. Bach, J. M. Forbes et al., “Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE),” The Journal of Clinical Investigation, vol. 108, no. 12, pp. 1853–1863, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Iehara, H. Takeoka, Y. Yamada, T. Kita, and T. Doi, “Advanced glycation end products modulate transcriptional regulation in mesangial cells,” Kidney International, vol. 50, no. 4, pp. 1166–1172, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Doi, H. Vlassara, M. Kirstein, Y. Yamada, G. E. Striker, and L. J. Striker, “Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 89, no. 7, pp. 2873–2877, 1992. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Meng, D. J. Nikolic-Paterson, and H. Y. Lan, “TGF-β: the master regulator of fibrosis,” Nature Reviews Nephrology, vol. 12, no. 6, pp. 325–338, 2016. View at Publisher · View at Google Scholar
  35. Y. B. Y. Sun, X. Qu, V. Howard et al., “Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance,” Kidney International, vol. 88, no. 2, pp. 286–298, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Kolavennu, L. Zeng, H. Peng, Y. Wang, and F. R. Danesh, “Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control,” Diabetes, vol. 57, no. 3, pp. 714–723, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Peng, D. Wu, B. Gao et al., “RhoA/rho-kinase contribute to the pathogenesis of diabetic renal disease,” Diabetes, vol. 57, no. 6, pp. 1683–1692, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. F. R. Danesh, M. M. Sadeghit, N. Amro et al., “3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 99, no. 12, pp. 8301–8305, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Hirose, T. Tanikawa, H. Mori, Y. Okada, and Y. Tanaka, “Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway,” FEBS Letters, vol. 584, no. 1, pp. 61–66, 2010. View at Publisher · View at Google Scholar · View at Scopus